<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312440348</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312440348</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Association between the valine/leucine<sup>247</sup> polymorphism of β<sub>2</sub>-glycoprotein I and susceptibility to anti-phospholipid syndrome: a meta-analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lee</surname><given-names>YH</given-names></name>
<xref ref-type="corresp" rid="corresp1-0961203312440348"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Choi</surname><given-names>SJ</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Ji</surname><given-names>JD</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Song</surname><given-names>GG</given-names></name>
</contrib>
</contrib-group>
<aff id="aff1-0961203312440348">Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea</aff>
<author-notes>
<corresp id="corresp1-0961203312440348">Young H Lee, Division of Rheumatology, Department of Internal Medicine, Korea University, Anam Hospital, Korea University College of Medicine, 126–1, Anam-dong 5-ga, Seongbuk-gu, Seoul 136–705, Korea Email: <email>lyhcgh@korea.ac.kr</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>21</volume>
<issue>8</issue>
<fpage>865</fpage>
<lpage>871</lpage>
<history>
<date date-type="received"><day>6</day><month>1</month><year>2012</year></date>
<date date-type="accepted"><day>2</day><month>2</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><bold>Objective:</bold> The objective of this paper is to explore whether the valine/leucine<sup>247</sup> (Val/Leu<sup>247</sup>) polymorphism of β<sub>2</sub>-glycoprotein I (β<sub>2</sub>GPI) confers susceptibility to anti-phospholipid syndrome (APS) and thrombosis and predicts positivity for anti-β<sub>2</sub>GPI antibodies. <bold>Methods:</bold> A meta-analysis was conducted on the associations between the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism and susceptibility to APS and thrombosis and positivity for anti-β<sub>2</sub>GPI. <bold>Results:</bold> A total of 1507 patients with APS and 1450 controls in 12 comparative studies were included in this meta-analysis. Meta-analysis of the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism showed significant associations between the β<sub>2</sub>GPI Val allele and APS, thrombosis, and anti-β<sub>2</sub>GPI positivity (odds ratio (OR) 1.316, 95% confidence interval (CI) 1.068–1.621, <italic>p</italic> = 0.010; OR 1.908, 95% CI 1.195–3.046, <italic>p</italic> = 0.007; OR 1.630, 95% CI 1.018–2.609, <italic>p</italic> = 0.042, respectively). A direct comparison between anti-β<sub>2</sub>GPI-positive and -negative patients revealed that the frequency of the Val allele was significantly higher in anti-β<sub>2</sub>GPI-positive patents (OR 1.514, 95% CI 1.017–1.253, <italic>p</italic> = 0.041). Furthermore, a direct comparison between thrombosis-positive and -negative patients also indicated that the Val/Val + Val/Leu and the Val/Val vs. Leu/Leu genotypes of the β<sub>2</sub>GPI polymorphism were significantly elevated in patients with thrombosis (OR 2.817, 95% CI 1.200–6.610, <italic>p</italic> = 0.017; OR 3.312, 95% CI 1.338–8.200, <italic>p</italic> = 0.010, respectively). <bold>Conclusion:</bold> This meta-analysis shows that the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism is associated with susceptibility to APS and thrombosis and with anti-β<sub>2</sub>GPI positivity.</p>
</abstract>
<kwd-group>
<kwd>Anti-phospholipid syndrome</kwd>
<kwd>meta-analysis</kwd>
<kwd>polymorphism</kwd>
<kwd>β<sub>2</sub>-glycoprotein I</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203312440348" sec-type="intro"><title>Introduction</title>
<p>Anti-phospholipid syndrome (APS) is an autoimmune disease characterized by arterial/venous thrombosis and recurrent fetal loss in the presence of anti-phospholipid (aPL) antibodies, such as lupus anticoagulant, anti-cardiolipin (aCL) antibodies and anti-β<sub>2</sub>glycoprotein-I (anti-β<sub>2</sub>GPI) antibodies.<sup><xref ref-type="bibr" rid="bibr1-0961203312440348">1</xref>,<xref ref-type="bibr" rid="bibr2-0961203312440348">2</xref></sup> Although the etiology of APS is not fully understood, it has been suggested to occur when an individual with genetic susceptibility to the disease is exposed to certain environmental factors.<sup><xref ref-type="bibr" rid="bibr3-0961203312440348">3</xref></sup></p>
<p>aCL is directed against phospholipid-binding proteins, mainly β<sub>2</sub>GPI, which consists of a single polypeptide chain (326 amino acids) composed of five homologous domains of approximately 60 amino acids each (designated domains I to V) and domain V contains the major phospholipid bind site.<sup><xref ref-type="bibr" rid="bibr4-0961203312440348">4</xref></sup> The mechanism by which anti-β<sub>2</sub>GPI recognizes β<sub>2</sub>GPI remains unclear. However, several epitopes for anti-β<sub>2</sub>GPI antibodies have been known. Especially, the domain I of β<sub>2</sub>GPI is recognized as one of the major epitopes.<sup><xref ref-type="bibr" rid="bibr4-0961203312440348">4</xref></sup> The β<sub>2</sub>GPI gene, which maps to chromosome 17q23–24, has four major polymorphisms at positions 88, 247, 306 and 316.<sup><xref ref-type="bibr" rid="bibr5-0961203312440348">5</xref></sup> However, the effects of these polymorphisms on the properties of β<sub>2</sub>GPI have not been determined. The valine/leucine<sup>247</sup> (Val/Leu<sup>247</sup>) polymorphism is located in domain V of β<sub>2</sub>GPI, which is a potential epitope site for anti-β<sub>2</sub>GPI antibodies.<sup><xref ref-type="bibr" rid="bibr6-0961203312440348">6</xref></sup> Furthermore, a polymorphism on or near the phospholipid-binding site of β<sub>2</sub>GPI could affect the binding or production of aCL.</p>
<p>The β<sub>2</sub>GPI Val<sup>247</sup> allele has been reported to be associated with a higher frequency of anti-β<sub>2</sub>GPI and stronger reactivity with anti-β<sub>2</sub>GPI than the β<sub>2</sub>GPI Leu allele, which suggests that this allele may be a genetic susceptibility factor for the development of APS.<sup><xref ref-type="bibr" rid="bibr7-0961203312440348">7</xref></sup></p>
<p>The β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism has been studied in the context of susceptibility to APS, thrombosis and anti-β<sub>2</sub>GPI positivity.<sup><xref ref-type="bibr" rid="bibr8-0961203312440348">8</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr17-0961203312440348">17</xref></sup> However, published genetic association results for the polymorphism are controversial, which could be due to small sample sizes, low statistical power and/or clinical heterogeneity. Therefore, in order to overcome the limitations of individual studies, resolve inconsistencies and reduce the likelihood that random errors are responsible for reported false positive or false negative associations,<sup><xref ref-type="bibr" rid="bibr18-0961203312440348">18</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr20-0961203312440348">20</xref></sup> we turned to meta-analysis. In the present study, we sought to determine whether the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism contributes to susceptibility to APS, thrombosis and anti-β<sub>2</sub>GPI positivity using a meta-analysis approach.</p>
<sec id="sec2-0961203312440348" sec-type="materials|methods"><title>Materials and methods</title>
<sec id="sec3-0961203312440348"><title>Identification of eligible studies and data extraction</title>
<p>A literature search was conducted for studies that examined associations between the β<sub>2</sub>GPI polymorphism and APS. We utilized the MEDLINE citation index to identify articles (up to December 2011) that examined the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism in APS patients and controls. In addition, all references mentioned in identified articles were reviewed to identify studies not indexed by MEDLINE. The following key words and subject terms were searched, ‘antiphospholipid syndrome’, ‘APS’ and ‘polymorphism’ and the following information was extracted from each study identified: author; year of publication; ethnicity of the study population; demographics; numbers of cases and controls; the frequencies of genotypes and alleles of the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism.</p></sec>
<sec id="sec4-0961203312440348"><title>Evaluation of publication bias and study quality</title>
<p>Funnel plots are used to detect publication bias, but require a range of studies of varying sizes and subjective judgments and, thus, we evaluated publication bias using Egger’s linear regression test,<sup><xref ref-type="bibr" rid="bibr21-0961203312440348">21</xref></sup> which measures funnel plot asymmetry on a natural logarithm scale of odds ratios (ORs). The χ<sup>2</sup> test was used to determine if observed genotype frequencies in controls conformed to Hardy–Weinberg (H-W) expectations.</p></sec>
<sec id="sec5-0961203312440348"><title>Evaluations of statistical associations</title>
<p>We performed meta-analyses using: (1) the allelic contrast (Val vs. Leu); (2) the recessive (Val/Val vs. Val/Leu + Leu/Leu); (3) the dominant (Val/Val + Val/Leu vs. Leu/Leu); (4) the additive (Val/Val vs. Leu/Leu) models. Point estimates of risks, ORs and 95% confidence intervals (CI) were estimated for each study. In addition, within- and between-study variations and heterogeneities were assessed using Cochran’s Q-statistic. This heterogeneity test assesses the null hypothesis that all studies evaluated the same effect. The effect of heterogeneity was quantified using I<sup>2</sup>, which ranges between 0 and 100% and represents the proportion of between-study variability attributable to heterogeneity rather than chance.<sup><xref ref-type="bibr" rid="bibr22-0961203312440348">22</xref></sup> I<sup>2</sup> values of 25%, 50% and 75% were nominally defined as low, moderate and high estimates. The fixed effects model assumes that a genetic factor has a similar effect on vasculitis susceptibility across all studies investigated and that observed variations among studies are caused by chance alone.<sup><xref ref-type="bibr" rid="bibr23-0961203312440348">23</xref></sup> The random effects model assumes that different studies show substantial diversity and assesses both within-study sampling error and between-study variance.<sup><xref ref-type="bibr" rid="bibr24-0961203312440348">24</xref></sup> When study groups are homogeneous, the two models are similar, but if this is not the case the random effects model usually provides wider CI than the fixed effects model. The random effects model is best used in the presence of significant between-study heterogeneity.<sup><xref ref-type="bibr" rid="bibr24-0961203312440348">24</xref></sup> Statistical manipulations were undertaken using a Comprehensive Meta-Analysis computer program (Biosta, Englewood, USA).</p></sec></sec></sec>
<sec id="sec6-0961203312440348" sec-type="results"><title>Results</title>
<sec id="sec7-0961203312440348"><title>Studies included in the meta-analysis</title>
<p>Altogether, 29 studies were identified by electronic and manual searches and 11 were selected for a full-text review based on title and abstract details.<sup><xref ref-type="bibr" rid="bibr8-0961203312440348">8</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr17-0961203312440348">17</xref>,<xref ref-type="bibr" rid="bibr25-0961203312440348">25</xref></sup> One of the 11 was excluded, because it did not include the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism.<sup><xref ref-type="bibr" rid="bibr25-0961203312440348">25</xref></sup> In addition, one of the eligible studies contained data on three different ethnic groups<sup><xref ref-type="bibr" rid="bibr17-0961203312440348">17</xref></sup> and these were treated independently.<sup><xref ref-type="bibr" rid="bibr16-0961203312440348">16</xref>,<xref ref-type="bibr" rid="bibr25-0961203312440348">25</xref></sup> Thus, a total of 12 populations were considered in the meta-analysis and, in total, these contained 1507 patients and 1450 controls<sup><xref ref-type="bibr" rid="bibr8-0961203312440348">8</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr12-0961203312440348">12</xref>,<xref ref-type="bibr" rid="bibr14-0961203312440348">14</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr16-0961203312440348">16</xref></sup> (<xref ref-type="table" rid="table1-0961203312440348">Table 1</xref>). These 12 populations encompassed four European, three South American, two Asian, one African American, one mixed and one population of unknown ethnicity. In 10 of these 12 populations, the β<sub>2</sub>GPI polymorphism was examined in APS patients and controls, in eight the polymorphism was examined in anti-β<sub>2</sub>GPI (+) patients and controls, in nine the polymorphism was examined in anti-β<sub>2</sub>GPI (+) and anti-β<sub>2</sub>GPI (−) patients, in four the polymorphism was examined in thrombosis (+) patients and controls and in three the polymorphism was examined in thrombosis (+) and thrombosis (−) patients. <xref ref-type="table" rid="table1-0961203312440348">Table 1</xref> summarizes the details of the individual studies included in the meta-analysis.
<table-wrap id="table1-0961203312440348" position="float"><label>Table 1</label><caption><p>Details of the individual studies included in the meta-analysis</p></caption>
<graphic alternate-form-of="table1-0961203312440348" xlink:href="10.1177_0961203312440348-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Author<sup>Ref</sup></th>
<th rowspan="2">Year</th>
<th rowspan="2">Ethnicity</th>
<th colspan="2">Numbers<hr/></th>
<th colspan="3">Association <italic>p</italic>-values with the β<sub>2</sub>GPI polymorphism<hr/></th></tr>
<tr><th>Case</th>
<th>Control</th>
<th>APS</th>
<th>Anti-β<sub>2</sub>GPI</th>
<th>Thrombosis</th></tr></thead>
<tbody align="left">
<tr>
<td>Pernambuco-Climaco et al.<sup><xref ref-type="bibr" rid="bibr8-0961203312440348">8</xref></sup></td>
<td>2009</td>
<td>South American</td>
<td>94</td>
<td>100</td>
<td>0.006</td>
<td>0.224</td>
<td>0.002</td></tr>
<tr>
<td>Palomo et a.l<sup><xref ref-type="bibr" rid="bibr9-0961203312440348">9</xref></sup></td>
<td>2007</td>
<td>South American</td>
<td>149</td>
<td>160</td>
<td>NA<sup><xref ref-type="table-fn" rid="table-fn2-0961203312440348">a</xref></sup></td>
<td>0.379</td>
<td>1.5 × 10<sup>−4</sup></td></tr>
<tr>
<td>Swadzba et al.<sup><xref ref-type="bibr" rid="bibr10-0961203312440348">10</xref></sup></td>
<td>2006</td>
<td>European</td>
<td>338</td>
<td>93</td>
<td>0.768</td>
<td>0.243</td>
<td>0.746</td></tr>
<tr>
<td>von Scheven and Elder<sup><xref ref-type="bibr" rid="bibr11-0961203312440348">11</xref></sup></td>
<td>2005</td>
<td>Mixed</td>
<td>41</td>
<td>17</td>
<td>NA</td>
<td>0.150<sup><xref ref-type="table-fn" rid="table-fn3-0961203312440348">b</xref></sup></td>
<td>NA</td></tr>
<tr>
<td>Yasuda et al.<sup><xref ref-type="bibr" rid="bibr12-0961203312440348">12</xref></sup></td>
<td>2005</td>
<td>Asian</td>
<td>65</td>
<td>122</td>
<td>0.270</td>
<td>0.022</td>
<td>NA</td></tr>
<tr>
<td>Camilleri et al.<sup><xref ref-type="bibr" rid="bibr13-0961203312440348">13</xref></sup></td>
<td>2003</td>
<td>European</td>
<td>173</td>
<td>308</td>
<td>0.844</td>
<td>0.013<sup><xref ref-type="table-fn" rid="table-fn4-0961203312440348">c</xref></sup></td>
<td>NA</td></tr>
<tr>
<td>Prieto et al.<sup><xref ref-type="bibr" rid="bibr14-0961203312440348">14</xref></sup></td>
<td>2003</td>
<td>South American</td>
<td>33</td>
<td>106</td>
<td>0.077</td>
<td>0.017</td>
<td>0.012</td></tr>
<tr>
<td>Kamboh et al.<sup><xref ref-type="bibr" rid="bibr15-0961203312440348">15</xref></sup></td>
<td>1999</td>
<td>Unknown</td>
<td>220</td>
<td>166</td>
<td>0.064</td>
<td>NA</td>
<td>NA</td></tr>
<tr>
<td>Atusmi et al.<sup><xref ref-type="bibr" rid="bibr16-0961203312440348">16</xref></sup></td>
<td>1999</td>
<td>European</td>
<td>94</td>
<td>78</td>
<td>0.837</td>
<td>0.126</td>
<td>NA</td></tr>
<tr>
<td>Hirose et al.<sup><xref ref-type="bibr" rid="bibr17-0961203312440348">17</xref></sup></td>
<td>1999</td>
<td>Asian</td>
<td>100</td>
<td>100</td>
<td>1.3 × 10<sup>−6</sup></td>
<td>&lt;1 × 10<sup>−8</sup></td>
<td>NA</td></tr>
<tr>
<td>Hirose et al.<sup><xref ref-type="bibr" rid="bibr17-0961203312440348">17</xref></sup></td>
<td>1999</td>
<td>European</td>
<td>100</td>
<td>100</td>
<td>0.915</td>
<td>NA</td>
<td>NA</td></tr>
<tr>
<td>Hirose et al.<sup><xref ref-type="bibr" rid="bibr17-0961203312440348">17</xref></sup></td>
<td>1999</td>
<td>African American</td>
<td>100</td>
<td>100</td>
<td>0.688</td>
<td>NA</td>
<td>NA</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203312440348"><p>Ref: reference; β<sub>2</sub>GPI: β<sub>2</sub>-glycoprotein I; APS: anti-phospholipid syndrome; NA: not available; aPL: anti-phospholipid antibodies.</p></fn>
<fn id="table-fn2-0961203312440348"><label>a</label><p>All patients with thrombosis, but not all with APS.</p></fn>
<fn id="table-fn3-0961203312440348"><label>b</label><p>aPL (+) vs. aPL (−).</p></fn>
<fn id="table-fn4-0961203312440348"><label>c</label><p>aPL antibodies.</p></fn></table-wrap-foot>
</table-wrap></p></sec>
<sec id="sec8-0961203312440348"><title>Meta-analysis of the associations between the t<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism and APS and anti-P<sub>2</sub>GPI positivity</title>
<p>Meta-analysis of the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism showed significant associations between its V allele with APS and with anti-β<sub>2</sub>GPI positivity (OR 1.316, 95% CI 1.068–1.621, <italic>p</italic> = 0.010; OR 1.630, 95% CI 1.018–2.609, <italic>p</italic> = 0.042, respectively; Figures <xref ref-type="fig" rid="fig1-0961203312440348">1</xref> and <xref ref-type="fig" rid="fig2-0961203312440348">2</xref>, <xref ref-type="table" rid="table2-0961203312440348">Table 2</xref>). Analysis using the recessive or additive models also revealed a significant association between the polymorphism and APS (<xref ref-type="table" rid="table2-0961203312440348">Table 2</xref>). Furthermore, a direct comparison between anti-β<sub>2</sub>GPI-positive and -negative patients revealed that the frequency of the V allele was significantly higher among anti-β<sub>2</sub>GPI-positive patents (OR 1.514, 95% CI 1.017–1.2.253, <italic>p</italic> = 0.041; <xref ref-type="table" rid="table2-0961203312440348">Table 2</xref>). Two studies included aPL instead of anti-β<sub>2</sub>GPI, but we restricted the analysis to anti-β<sub>2</sub>GPI. However, when studies on aPL were excluded in the meta-analysis of the relationship between the polymorphism and anti-β<sub>2</sub>GPI status, the overall results were not substantially affected.
<fig id="fig1-0961203312440348" position="float"><label>Figure 1</label><caption><p>Odds ratios and 95% confidence intervals (CI) of individual studies and pooled data for the association between the valine (Val) allele of the β<sub>2</sub>glycoprotein-I Val/leucine<sup>247</sup> polymorphism and anti-phospholipid syndrome (APS).</p></caption><graphic xlink:href="10.1177_0961203312440348-fig1.tif"/></fig>
<fig id="fig2-0961203312440348" position="float"><label>Figure 2</label><caption><p>Odds ratios and 95% confidence intervals (CI) of individual studies and pooled data for the association between the valine (Val) allele of the β<sub>2</sub>glycoprotein-I (β<sub>2</sub>GPI) Val/leucine<sup>247</sup> polymorphism and anti-β<sub>2</sub>GPI.</p></caption><graphic xlink:href="10.1177_0961203312440348-fig2.tif"/></fig>
<table-wrap id="table2-0961203312440348" position="float"><label>Table 2</label><caption><p>Meta-analysis of the association between the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism and APS</p></caption>
<graphic alternate-form-of="table2-0961203312440348" xlink:href="10.1177_0961203312440348-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Diseases</th>
<th rowspan="2">Comparison</th>
<th rowspan="2">No. of studies</th>
<th colspan="3">Test of association<hr/></th>
<th colspan="3">Test of heterogeneity<hr/></th></tr>
<tr><th>OR</th>
<th>95% CI</th>
<th><italic>p-</italic>val</th>
<th>Model</th>
<th><italic>p-val</italic></th>
<th><italic>I<sup>2</sup></italic></th></tr></thead>
<tbody align="left">
<tr>
<td rowspan="4">APS vs. control</td>
<td>Val vs. Leu</td>
<td>10</td>
<td>1.316</td>
<td>1.068–1.621</td>
<td>0.010</td>
<td>R</td>
<td>0.004</td>
<td>62.7</td></tr>
<tr>
<td>Val/Val + Val/Leu vs. Leu/Leu</td>
<td>8</td>
<td>1.171</td>
<td>0.726–1.889</td>
<td>0.516</td>
<td>R</td>
<td>0.005</td>
<td>65.2</td></tr>
<tr>
<td>Val/Val vs. Val/Leu + Leu/Leu</td>
<td>8</td>
<td>1.878</td>
<td>1.186–2.976</td>
<td>0.007</td>
<td>R</td>
<td>0.000</td>
<td>80.8</td></tr>
<tr>
<td>Val/Val vs. Leu/Leu</td>
<td>8</td>
<td>1.778</td>
<td>1.028–3.077</td>
<td>0.040</td>
<td>R</td>
<td>0.010</td>
<td>62.0</td></tr>
<tr>
<td rowspan="4">Anti-β<sub>2</sub>GPI (+) vs. control</td>
<td>Val vs. Leu</td>
<td>8</td>
<td>1.630</td>
<td>1.018–2.609</td>
<td>0.042</td>
<td>R</td>
<td>0.000</td>
<td>82.1</td></tr>
<tr>
<td>Val/Val + Val/Leu vs. Leu/Leu</td>
<td>6</td>
<td>0.866</td>
<td>0.256–2.930</td>
<td>0.817</td>
<td>R</td>
<td>0.000</td>
<td>88.9</td></tr>
<tr>
<td>Val/Val vs. Val/Leu + Leu/Leu</td>
<td>6</td>
<td>2.980</td>
<td>1.228–7.234</td>
<td>0.016</td>
<td>R</td>
<td>0.000</td>
<td>84.5</td></tr>
<tr>
<td>Val/Val vs. Leu/Leu</td>
<td>6</td>
<td>1.886</td>
<td>0.418–8.511</td>
<td>0.409</td>
<td>R</td>
<td>0.000</td>
<td>89.4</td></tr>
<tr>
<td rowspan="4">Anti-β<sub>2</sub>GPI (+) vs. Anti-β<sub>2</sub>GPI (−)</td>
<td>Val vs. Leu</td>
<td>9</td>
<td>1.514</td>
<td>1.017–2.253</td>
<td>0.041</td>
<td>R</td>
<td>0.000</td>
<td>72.1</td></tr>
<tr>
<td>Val/Val + Val/Leu vs. Leu/Leu</td>
<td>7</td>
<td>0.706</td>
<td>0.393–1.269</td>
<td>0.245</td>
<td>R</td>
<td>0.082</td>
<td>46.5</td></tr>
<tr>
<td>Val/Val vs. Val/Leu + Leu/Leu</td>
<td>7</td>
<td>1.977</td>
<td>0.920–4.247</td>
<td>0.081</td>
<td>R</td>
<td>0.010</td>
<td>64.0</td></tr>
<tr>
<td>Val/Val vs. Leu/Leu</td>
<td>7</td>
<td>1.742</td>
<td>0.499–6.85</td>
<td>0.348</td>
<td>R</td>
<td>0.001</td>
<td>72.9</td></tr>
<tr>
<td rowspan="4">Thrombosis (+) vs. control</td>
<td>Val vs. Leu</td>
<td>4</td>
<td>1.908</td>
<td>1.195–3.046</td>
<td>0.007</td>
<td>R</td>
<td>0.019</td>
<td>69.7</td></tr>
<tr>
<td>Val/Val + Val/Leu vs. Leu/Leu</td>
<td>4</td>
<td>2.693</td>
<td>1.636–4.429</td>
<td>9.6 × 10<sup>–5</sup></td>
<td>F</td>
<td>0.668</td>
<td>0</td></tr>
<tr>
<td>Val/Val vs. Val/Leu + Leu/Leu</td>
<td>4</td>
<td>2.723</td>
<td>1.018–7.287</td>
<td>0.046</td>
<td>F</td>
<td>0.000</td>
<td>87.8</td></tr>
<tr>
<td>Val/Val vs. Leu/Leu</td>
<td>4</td>
<td>3.152</td>
<td>1.898–5.233</td>
<td>9.0 × 10<sup>–6</sup></td>
<td>F</td>
<td>0.721</td>
<td>0</td></tr>
<tr>
<td rowspan="4">Thrombosis (+) vs. Thrombosis (−)</td>
<td>Val vs. Leu</td>
<td>3</td>
<td>1.256</td>
<td>0.920–1.714</td>
<td>0.152</td>
<td>F</td>
<td>0.112</td>
<td>54.2</td></tr>
<tr>
<td>Val/Val + Val/Leu vs. Leu/Leu</td>
<td>3</td>
<td>2.817</td>
<td>1.200–6.610</td>
<td>0.017</td>
<td>F</td>
<td>0.436</td>
<td>0</td></tr>
<tr>
<td>Val/Val vs. Val/Leu + Leu/Leu</td>
<td>3</td>
<td>1.027</td>
<td>0.697–1.514</td>
<td>0.893</td>
<td>F</td>
<td>0.102</td>
<td>56.1</td></tr>
<tr>
<td>Val/Val vs. Leu/Leu</td>
<td>3</td>
<td>3.312</td>
<td>1.338–8.200</td>
<td>0.010</td>
<td>F</td>
<td>0.420</td>
<td>0</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0961203312440348"><p>β<sub>2</sub>GPI: β<sub>2</sub>-glycoprotein I; Val: valine; Leu: leucine; APS: antiphospholipid syndrome; OR: odds ratio; CI: confidence interval; F: fixed effects model; R: random effects model.</p></fn></table-wrap-foot>
</table-wrap></p></sec>
<sec id="sec9-0961203312440348"><title>Meta-analysis of the association between the e<sub>2</sub>GPI polymorphism and thrombosis</title>
<p>Meta-analysis showed a significant association between the presence of thrombosis and the β<sub>2</sub>GPI V allele (OR 1.908, 95% CI 1.195–3.046, <italic>p</italic> = 0.007) (<xref ref-type="fig" rid="fig3-0961203312440348">Figure 3</xref>, <xref ref-type="table" rid="table2-0961203312440348">Table 2</xref>). In particular, analysis using the recessive, dominant or additive models revealed significant associations between thrombosis and the β<sub>2</sub>GPI polymorphism (<xref ref-type="table" rid="table2-0961203312440348">Table 2</xref>). A direct comparison between thrombosis-positive and -negative patients indicated that the frequencies of the Val/Val + Val/Leu genotype and the Val/Val vs. Leu/Leu genotype of the β<sub>2</sub>GPI polymorphism were significantly higher in patients with thrombosis (OR 2.817, 95% CI 1.200–6.610, <italic>p</italic> = 0.017; OR 3.312, 95% CI 1.338–8.200, <italic>p</italic> = 0.010, respectively; <xref ref-type="table" rid="table2-0961203312440348">Table 2</xref>).
<fig id="fig3-0961203312440348" position="float"><label>Figure 3</label><caption><p>Odds ratios and 95% confidence intervals (CI) of individual studies and pooled data for the association between the valine (Val) allele of the β<sub>2</sub>glycoprotein-I Val/leucine<sup>247</sup> polymorphism and thrombosis.</p></caption><graphic xlink:href="10.1177_0961203312440348-fig3.tif"/></fig></p></sec>
<sec id="sec10-0961203312440348"><title>Heterogeneity and publication bias</title>
<p>The distributions of the genotypes of the β<sub>2</sub>GPI polymorphism in the control groups were consistent with the H-W equilibrium in populations studied, except for three populations.<sup><xref ref-type="bibr" rid="bibr8-0961203312440348">8</xref>,<xref ref-type="bibr" rid="bibr10-0961203312440348">10</xref>,<xref ref-type="bibr" rid="bibr17-0961203312440348">17</xref></sup> Deviation from the H-W equilibrium among controls implies the possibility of selection bias or genotyping errors. However, when these three populations were excluded, the overall results were not substantially affected. Some between-study heterogeneity was found by meta-analyses of APS vs. control, anti-β<sub>2</sub>GPI (+) vs. control and anti-β<sub>2</sub>GPI (+) vs. anti-β<sub>2</sub>GPI (−). However, no between-study heterogeneity was found by meta-analyses of the β<sub>2</sub>GPI polymorphism in thrombosis (+) vs. thrombosis (−), except for the V allele analysis (<xref ref-type="table" rid="table2-0961203312440348">Table 2</xref>). Publication bias causes a disproportionate number of positive studies and poses a problem for meta-analyses, but Egger’s regression test showed no evidence of publication bias in any of the meta-analyses conducted during the present study (Egger’s regression test <italic>p</italic>-values &gt;0.1).</p></sec></sec>
<sec id="sec11-0961203312440348" sec-type="discussion"><title>Discussion</title>
<p>APS is a complex autoimmune disease that demonstrates gene–gene and gene–environmental involvements. In particular, genetic variants may affect susceptibility to and the clinical manifestations of APS.Thus, interest in genetic susceptibility to APS and the clinical manifestations of genetic variants have encouraged studies on the effects of genetic polymorphisms on the pathogenesis of APS.<sup><xref ref-type="bibr" rid="bibr3-0961203312440348">3</xref></sup></p>
<p>However, results on the association between the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism and APS remain inconclusive.<sup><xref ref-type="bibr" rid="bibr8-0961203312440348">8</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr17-0961203312440348">17</xref></sup> In this meta-analysis, we combined data from published studies on genetic associations between the most commonly studied polymorphism of the β<sub>2</sub>GPI gene, namely, the Val/Leu<sup>247</sup> polymorphism and APS. Our meta-analysis showed a significant association between the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism and APS, thrombosis and anti-β<sub>2</sub>GPI positivity. In particular, a direct comparison between anti-β<sub>2</sub>GPI-positive and -negative patients revealed that the frequency of the Val allele was significantly higher in anti-β<sub>2</sub>GPI-positive patents (OR 1.514, 95% CI 1.017–1.253, <italic>p</italic> = 0.041). Furthermore, patients with anti-β<sub>2</sub>GPI antibody had a significantly higher V allele frequency than patients without anti-β<sub>2</sub>GPI. In addition, a direct comparison between thrombosis-positive and -negative patients also indicated a significant association between the β<sub>2</sub>GPI polymorphism and presence of thrombosis, suggesting that the β<sub>2</sub>GPI polymorphism is a risk factor of the development of thrombosis. Also, patients with thrombosis had a greater Val allele more frequently than did patients without thrombosis.</p>
<p>The strength of our results was based on large sample sizes included in this meta-analysis compared to subject numbers from individual studies. Meta-analysis of individual studies is a method to overcome the problem of small sample size and inadequate statistical power of genetic studies of complex traits and integrate previous research, providing increased statistical power and resolution by pooling the results of independent analyses. Results from the article with the biggest population studied were negative.<sup><xref ref-type="bibr" rid="bibr10-0961203312440348">10</xref></sup> However, 1507 APS patients were included and compared to 1450 healthy controls in this meta-analysis and we determined the contribution of the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism to APS, thrombosis and anti-β<sub>2</sub>GPI using meta-analysis.</p>
<p>Then how could the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism affect susceptibility to APS and thrombosis and anti-β<sub>2</sub>GPI positivity? β<sub>2</sub>GPI is a major target antigen of aCL and the protein level of β<sub>2</sub>GPI is under genetic control. The β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism affects the electrostatic interaction between domains IV and V of β<sub>2</sub>GPI and, thus, causes structural changes at the autoantibody recognition site, which would affect affinity between anti-β<sub>2</sub>GPI and epitopes of β<sub>2</sub>GPI.<sup><xref ref-type="bibr" rid="bibr12-0961203312440348">12</xref></sup> Thus, the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism may affect the antigenicity of β<sub>2</sub>GPI for anti-β<sub>2</sub>GPI. In a previous study, anti-β<sub>2</sub>GPI was found to show more binding affinity for recombinant Val β<sub>2</sub>GPI than recombinant Leu β<sub>2</sub>GPI.<sup><xref ref-type="bibr" rid="bibr12-0961203312440348">12</xref></sup></p>
<p>A small alteration in the conformation of β<sub>2</sub>GPI arising from the Val/Leu substitution at position 247 could affect susceptibility to APS and thrombosis and anti-β<sub>2</sub>GPI positivity by increasing the propensity in patients with APS to generate autoreactive T cell clones. Ito et al.<sup><xref ref-type="bibr" rid="bibr26-0961203312440348">26</xref></sup> showed that CD4+ T cell clones react with peptide fragments, including amino acid positions 244–264 of β<sub>2</sub>GPI. Our meta-analysis findings are consistent with the notion that changes in β<sub>2</sub>GPI protein structure induce the generation of an antigenic β<sub>2</sub>GPI.</p>
<p>The present study has some limitations that should be considered. First, publication bias, heterogeneity and confounding factors may have distorted the meta-analysis. Data were not stratified by variables, such as primary or secondary APS, due to insufficient and limited information. Second, the frequencies of the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism are quite different among races, which may affect the statistical significance in each small-size study. Limited data also prevented ethnic-specific meta-analysis. Thus, studies are required on different ethnic groups to clarify the role of the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism more comprehensively in APS.</p>
<p>In conclusion, this meta-analysis of the association between the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism and APS shows that this polymorphism is weakly associated with susceptibility to APS and thrombosis and anti-β<sub>2</sub>GPI positivity. Furthermore, APS patients with anti-β<sub>2</sub>GPI positivity or thrombosis more frequently expressed the Val allele of the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism than APS patients without anti-β<sub>2</sub>GPI positivity or thrombosis. Accordingly, our findings support the notion that the β<sub>2</sub>GPI Val/Leu<sup>247</sup> polymorphism plays a role, but is probably not crucial in the pathogenesis of APS by influencing development of anti-β<sub>2</sub>GPI and thrombosis.</p></sec>
</body>
<back>
<sec id="sec12-0961203312440348"><title>Funding</title>
<p>This study was supported by a grant from Korea University Medical Center.</p></sec>
<sec id="sec13-0961203312440348"><title>Conflict of interest</title>
<p>None declared.</p></sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312440348"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miyakis</surname><given-names>S</given-names></name><name><surname>Lockshin</surname><given-names>MD</given-names></name><name><surname>Atsumi</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)</article-title>. <source>J Thromb Haemost</source> <year>2006</year>; <volume>4</volume>: <fpage>295</fpage>–<lpage>306</lpage>.</citation></ref>
<ref id="bibr2-0961203312440348"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>YJ</given-names></name><name><surname>Yun</surname><given-names>GW</given-names></name><name><surname>Song</surname><given-names>IC</given-names></name><etal/></person-group>. <article-title>Clinical implications of elevated antiphospholipid antibodies in adult patients with primary immune thrombocytopenia</article-title>. <source>Korean J Intern Med</source> <year>2011</year>; <volume>26</volume>: <fpage>449</fpage>–<lpage>454</lpage>.</citation></ref>
<ref id="bibr3-0961203312440348"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castro-Marrero</surname><given-names>J</given-names></name><name><surname>Balada</surname><given-names>E</given-names></name><name><surname>Vilardell-Tarres</surname><given-names>M</given-names></name><name><surname>Ordi-Ros</surname><given-names>J</given-names></name></person-group>. <article-title>Genetic risk factors of thrombosis in the antiphospholipid syndrome</article-title>. <source>Br J Haematol</source> <year>2009</year>; <volume>147</volume>: <fpage>289</fpage>–<lpage>296</lpage>.</citation></ref>
<ref id="bibr4-0961203312440348"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galli</surname><given-names>M</given-names></name><name><surname>Comfurius</surname><given-names>P</given-names></name><name><surname>Maassen</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor</article-title>. <source>Lancet</source> <year>1990</year>; <volume>335</volume>: <fpage>1544</fpage>–<lpage>1547</lpage>.</citation></ref>
<ref id="bibr5-0961203312440348"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McNeil</surname><given-names>HP</given-names></name><name><surname>Simpson</surname><given-names>RJ</given-names></name><name><surname>Chesterman</surname><given-names>CN</given-names></name><name><surname>Krilis</surname><given-names>SA</given-names></name></person-group>. <article-title>Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>1990</year>; <volume>87</volume>: <fpage>4120</fpage>–<lpage>4124</lpage>.</citation></ref>
<ref id="bibr6-0961203312440348"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Igarashi</surname><given-names>M</given-names></name><name><surname>Matsuura</surname><given-names>E</given-names></name><name><surname>Igarashi</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Human beta2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system</article-title>. <source>Blood</source> <year>1996</year>; <volume>87</volume>: <fpage>3262</fpage>–<lpage>3270</lpage>.</citation></ref>
<ref id="bibr7-0961203312440348"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Atsumi</surname><given-names>T</given-names></name><name><surname>Bertolaccini</surname><given-names>ML</given-names></name><name><surname>Koike</surname><given-names>T</given-names></name></person-group>. <article-title>Genetics of antiphospholipid syndrome</article-title>. <source>Rheum Dis Clin North Am</source> <year>2001</year>; <volume>27</volume>: <fpage>565</fpage>–<lpage>572, vi</lpage>.</citation></ref>
<ref id="bibr8-0961203312440348"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pernambuco-Climaco</surname><given-names>JM</given-names></name><name><surname>Brochado</surname><given-names>MJ</given-names></name><name><surname>Freitas</surname><given-names>MV</given-names></name><name><surname>Roselino</surname><given-names>AM</given-names></name><name><surname>Louzada-Junior</surname><given-names>P</given-names></name></person-group>. <article-title>Val/Leu247 polymorphism of beta2-glycoprotein I in Brazilian patients with antiphospholipid syndrome – a genetic risk factor?</article-title> <source>Ann N Y Acad Sci</source> <year>2009</year>; <volume>1173</volume>: <fpage>509</fpage>–<lpage>514</lpage>.</citation></ref>
<ref id="bibr9-0961203312440348"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palomo</surname><given-names>I</given-names></name><name><surname>Pereira</surname><given-names>J</given-names></name><name><surname>Alarcon</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Val/Leu247 and Trp/Ser316 polymorphisms in beta 2 glycoprotein I and their association with thrombosis in unselected Chilean patients</article-title>. <source>Clin Rheumatol</source> <year>2007</year>; <volume>26</volume>: <fpage>302</fpage>–<lpage>307</lpage>.</citation></ref>
<ref id="bibr10-0961203312440348"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Swadzba</surname><given-names>J</given-names></name><name><surname>Sanak</surname><given-names>M</given-names></name><name><surname>Iwaniec</surname><given-names>T</given-names></name><name><surname>Dziedzina</surname><given-names>S</given-names></name><name><surname>Musial</surname><given-names>J</given-names></name></person-group>. <article-title>Valine/Leucine247 polymorphism of beta2-glycoprotein I in patients with antiphospholipid syndrome: lack of association with anti-beta2-glycoprotein I antibodies</article-title>. <source>Lupus</source> <year>2006</year>; <volume>15</volume>: <fpage>218</fpage>–<lpage>222</lpage>.</citation></ref>
<ref id="bibr11-0961203312440348"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>von Scheven</surname><given-names>E</given-names></name><name><surname>Elder</surname><given-names>ME</given-names></name></person-group>. <article-title>Association between beta2-glycoprotein I gene polymorphisms and pediatric SLE and antiphospholipid antibodies</article-title>. <source>Lupus</source> <year>2005</year>; <volume>14</volume>: <fpage>440</fpage>–<lpage>444</lpage>.</citation></ref>
<ref id="bibr12-0961203312440348"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yasuda</surname><given-names>S</given-names></name><name><surname>Atsumi</surname><given-names>T</given-names></name><name><surname>Matsuura</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Significance of valine/leucine247 polymorphism of beta2-glycoprotein I in antiphospholipid syndrome: increased reactivity of anti-beta2-glycoprotein I autoantibodies to the valine247 beta2-glycoprotein I variant</article-title>. <source>Arthritis Rheum</source> <year>2005</year>; <volume>52</volume>: <fpage>212</fpage>–<lpage>218</lpage>.</citation></ref>
<ref id="bibr13-0961203312440348"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Camilleri</surname><given-names>RS</given-names></name><name><surname>Mackie</surname><given-names>IJ</given-names></name><name><surname>Humphries</surname><given-names>SE</given-names></name><name><surname>Machin</surname><given-names>SJ</given-names></name><name><surname>Cohen</surname><given-names>H</given-names></name></person-group>. <article-title>Lack of association of beta2-glycoprotein I polymorphisms Val247Leu and Trp316Ser with antiphospholipid antibodies in patients with thrombosis and pregnancy complications</article-title>. <source>Br J Haematol</source> <year>2003</year>; <volume>120</volume>: <fpage>1066</fpage>–<lpage>1072</lpage>.</citation></ref>
<ref id="bibr14-0961203312440348"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prieto</surname><given-names>GA</given-names></name><name><surname>Cabral</surname><given-names>AR</given-names></name><name><surname>Zapata-Zuniga</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Valine/valine genotype at position 247 of the beta2-glycoprotein I gene in Mexican patients with primary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies</article-title>. <source>Arthritis Rheum</source> <year>2003</year>; <volume>48</volume>: <fpage>471</fpage>–<lpage>474</lpage>.</citation></ref>
<ref id="bibr15-0961203312440348"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kamboh</surname><given-names>MI</given-names></name><name><surname>Manzi</surname><given-names>S</given-names></name><name><surname>Mehdi</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Genetic variation in apolipoprotein H (beta2-glycoprotein I) affects the occurrence of antiphospholipid antibodies and apolipoprotein H concentrations in systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>1999</year>; <volume>8</volume>: <fpage>742</fpage>–<lpage>750</lpage>.</citation></ref>
<ref id="bibr16-0961203312440348"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Atsumi</surname><given-names>T</given-names></name><name><surname>Tsutsumi</surname><given-names>A</given-names></name><name><surname>Amengual</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Correlation between beta2-glycoprotein I valine/leucine247 polymorphism and anti-beta2-glycoprotein I antibodies in patients with primary antiphospholipid syndrome</article-title>. <source>Rheumatology (Oxford)</source> <year>1999</year>; <volume>38</volume>: <fpage>721</fpage>–<lpage>723</lpage>.</citation></ref>
<ref id="bibr17-0961203312440348"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirose</surname><given-names>N</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name><name><surname>Alberts</surname><given-names>AR</given-names></name><etal/></person-group>. <article-title>A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome</article-title>. <source>Arthritis Rheum</source> <year>1999</year>; <volume>42</volume>: <fpage>1655</fpage>–<lpage>1661</lpage>.</citation></ref>
<ref id="bibr18-0961203312440348"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Harley</surname><given-names>JB</given-names></name><name><surname>Nath</surname><given-names>SK</given-names></name></person-group>. <article-title>Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility</article-title>. <source>Eur J Hum Genet</source> <year>2006</year>; <volume>14</volume>: <fpage>364</fpage>–<lpage>371</lpage>.</citation></ref>
<ref id="bibr19-0961203312440348"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Rho</surname><given-names>YH</given-names></name><name><surname>Choi</surname><given-names>SJ</given-names></name><name><surname>Ji</surname><given-names>JD</given-names></name><name><surname>Song</surname><given-names>GG</given-names></name></person-group>. <article-title>Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis</article-title>. <source>Rheumatol Int</source> <year>2006</year>; <volume>27</volume>: <fpage>157</fpage>–<lpage>161</lpage>.</citation></ref>
<ref id="bibr20-0961203312440348"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Rho</surname><given-names>YH</given-names></name><name><surname>Choi</surname><given-names>SJ</given-names></name><etal/></person-group>. <article-title>The PTPN22 C1858T functional polymorphism and autoimmune diseases – a meta-analysis</article-title>. <source>Rheumatology (Oxford)</source> <year>2007</year>; <volume>46</volume>: <fpage>49</fpage>–<lpage>56</lpage>.</citation></ref>
<ref id="bibr21-0961203312440348"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Minder</surname><given-names>C</given-names></name></person-group>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source> <year>1997</year>; <volume>315</volume>: <fpage>629</fpage>–<lpage>634</lpage>.</citation></ref>
<ref id="bibr22-0961203312440348"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name></person-group>. <article-title>Quantifying heterogeneity in a meta-analysis</article-title>. <source>Stat Med</source> <year>2002</year>; <volume>21</volume>: <fpage>1539</fpage>–<lpage>1558</lpage>.</citation></ref>
<ref id="bibr23-0961203312440348"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>GD</given-names></name><name><surname>Phillips</surname><given-names>AN</given-names></name></person-group>. <article-title>Meta-analysis: principles and procedures</article-title>. <source>BMJ</source> <year>1997</year>; <volume>315</volume>: <fpage>1533</fpage>–<lpage>1537</lpage>.</citation></ref>
<ref id="bibr24-0961203312440348"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DerSimonian</surname><given-names>R</given-names></name><name><surname>Laird</surname><given-names>N</given-names></name></person-group>. <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source> <year>1986</year>; <volume>7</volume>: <fpage>177</fpage>–<lpage>188</lpage>.</citation></ref>
<ref id="bibr25-0961203312440348"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gushiken</surname><given-names>FC</given-names></name><name><surname>Arnett</surname><given-names>FC</given-names></name><name><surname>Ahn</surname><given-names>C</given-names></name><name><surname>Thiagarajan</surname><given-names>P</given-names></name></person-group>. <article-title>Polymorphism of beta2-glycoprotein I at codons 306 and 316 in patients with systemic lupus erythematosus and antiphospholipid syndrome</article-title>. <source>Arthritis Rheum</source> <year>1999</year>; <volume>42</volume>: <fpage>1189</fpage>–<lpage>1193</lpage>.</citation></ref>
<ref id="bibr26-0961203312440348"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Matsushita</surname><given-names>S</given-names></name><name><surname>Tokano</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Analysis of T cell responses to the beta 2-glycoprotein I-derived peptide library in patients with anti-beta 2-glycoprotein I antibody-associated autoimmunity</article-title>. <source>Hum Immunol</source> <year>2000</year>; <volume>61</volume>: <fpage>366</fpage>–<lpage>377</lpage>.</citation></ref>
</ref-list>
</back>
</article>